Photo taken from Robert Z. Orlowski/X
Feb 14, 2024, 13:50
Robert Z. Orlowski: Myeloma Paper of the Day
Robert Z. Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, posted on X/Twitter:
“Myeloma Paper of the Day: Matching-adjusted indirect comparison of efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma suggests that elranatamab may have better ORR and CR rates, and better PFS and OS.”
View additional information.
Source: Robert Z. Orlowski/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 18, 2024, 16:11
Dec 18, 2024, 15:52
Dec 18, 2024, 15:49
Dec 18, 2024, 15:45
Dec 18, 2024, 15:38
Dec 18, 2024, 15:11
Dec 18, 2024, 15:08
Dec 18, 2024, 14:24
Dec 18, 2024, 14:21